Antibodies targeting other co-inhibitory and co-stimulatory molecules such as Tim3, Lag3 and 4-1BB are being actively developed and investigated in clinical trials to further release the power of anti-tumor CD8+ T cells5,6. Here, TNFRSF9 is linked to neoplasm.